Petros Grivas

Trials

Studies that name Petros Grivas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:22 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05581589 · Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

  University of Washington · terminated · Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 · principal investigator
• Ph2
  NCT04383743 · Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

  University of Washington · completed · Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma · principal investigator
• N/A
  NCT03788746 · Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

  AstraZeneca · completed · Urothelial Carcinoma · study chair
• Ph1
  NCT03532451 · Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

  PrECOG, LLC. · completed · Bladder Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.